Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Inclusion Criteria: * Newly diagnosed mature B-lineage (CD20-positive) leukemia or lymphoma by the REAL classification of 1 of the following subtypes: * Diffuse large cell lymphoma * Burkitt's lymphoma * High-grade B-cell lymphoma (Burkitt-like) * No B-cell anaplastic large cell Ki-1 positive lymphomas and B-lymphoblastic lymphomas * One of the following FAB prognostic groups: * Group B (intermediate risk) * Group C (high risk) * Bone marrow involvement with at least 25% blasts and/or CNS involvement meeting 1 or more of the following criteria: * Any L3 blasts in cerebrospinal fluid * Cranial nerve palsy (if not explained by extracranial tumor) * Clinical spinal cord compression * Isolated intracerebral mass * Parameningeal extension (cranial and/or spinal) * Hepatitis B status known * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after study participation * No known history of congenital immune deficiency and/or laboratory evidence of acquired immune deficiency * No known G6PD deficiency (if receiving rasburicase) * No prior malignancies treated with systemic chemotherapy with alkylator or anthracycline therapy * No prior chemotherapy * At least 1 week since prior steroids except emergency steroids initiated within 72 hours of study entry * No prior radiotherapy except emergency radiotherapy initiated within 72 hours of study entry * No concurrent …